Pharmaceutical giant Sanofi (SNY -0.47%) and biotech Regeneron (REGN -0.84%) have announced the start of two late-stage clinical trials for their experimental rheumatoid arthritis drug sarilumab. This antibody is being tested in combination with methotrexate, a drug often used for the treatment of rheumatoid arthritis, and will be compared to Amgen (AMGN 0.22%) and Pfizer's (PFE 0.55%) Enbrel. In the following video, health-care analyst Max Macaluso discusses these clinical trials and how this drug could compete in the rheumatoid arthritis market.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Sanofi and Regeneron's Latest Partnership
By Max Macaluso
–
May 15, 2013 at 9:13PM
NASDAQ: SNY
Sanofi
Market Cap
$123B
Today's Change
(-0.47%) -$0.23
Current Price
$49.13
Price as of April 26, 2024, 4:00 p.m. ET
Late-stage clinical trials begin for this duo's experimental rheumatoid arthritis drug.
Max Macaluso, Ph.D. has no position in any stocks mentioned, and neither does The Motley Fool. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.